Medical AI Scribes Expose the Gap Between Efficiency and Patient Consent
An AI scribe can save a clinician time. It can also introduce an entirely new consent, privacy, and accountability workflow that most practices haven't built yet.
AI scribe adoption among Australian general practitioners increased from 22% in August 2024 to 40% in November 2025. That's a near-doubling in 15 months. These tools record, transcribe, and summarise doctor-patient conversations for medical notes. They've been used hundreds of millions of times globally. The federal health department has raised concerns about privacy, overseas data transfers, inconsistent patient consent, and regulatory gaps.
This pattern repeats across sectors: useful technology gets deployed before the surrounding workflow, consent process, and governance model mature. What begins as an administrative efficiency measure becomes a complex question the moment patient data enters the system.
The Classification Gap
Multiple regulatory bodies oversee different aspects of AI scribes. The Therapeutic Goods Administration, the Australian Health Practitioner Regulation Agency, and the Office of the Australian Information Commissioner each hold partial jurisdiction. The fragmentation creates gaps where accountability falls through the cracks.
AI scribes are only classified as "medical devices" under the Therapeutic Goods Act if they serve a therapeutic purpose. Some suppliers market their products as falling outside formal regulatory requirements. The TGA is reviewing this classification now, with findings expected soon.
The classification of technology determines its regulatory treatment. When tools exist in definitional ambiguity, oversight becomes optional rather than mandatory. Patients may not realise the notes from their consultation lack the safeguards applied to other medical technologies.
Data Residency Remains Invisible
The federal health department noted that some suppliers may be unaware that their cloud platforms transfer data outside Australia. This creates risks for patient data security that neither the healthcare provider nor the patient fully understands.
Data residency is often invisible to both parties in the consultation room. The clinician believes patient information stays within Australian jurisdiction. The patient assumes their doctor knows where their health records travel. Both assumptions can be wrong.
True informed consent requires that patients understand both the benefits and the limitations. Significant variation exists in how clinicians and practices obtain consent for AI scribe use. Agreement isn't the same as understanding. When patients don't know their data may leave the country, consent becomes procedural rather than genuine.
When Technology Acceptance Becomes Mandatory
The Consumer Health Forum reported increasing instances of patients being told they must find alternative providers if they refuse consent for AI scribe use. Technology acceptance is becoming a prerequisite for receiving care.
This shifts the traditional doctor-patient relationship. Patient autonomy includes the right to refuse technology-mediated consultations. When that refusal means reduced access to healthcare providers, choice becomes conditional rather than genuine.
Some AI scribe suppliers advertise a 30% revenue increase for health professionals with no additional hours or patient consultations. The economic incentive prioritises billable activities over improvements in direct patient care. Efficiency gains don't automatically translate to better patient outcomes. They can simply increase volume within the same time window.
Quality Limitations Carry Clinical Consequences
AI scribes rely on large language models. These systems have inherent limitations in quality and accuracy. The technology is subject to the same constraints as other LLM applications, with implications for patient safety, clinical accountability, and the integrity of national digital health infrastructure.
Medical notes aren't just administrative records. They inform treatment decisions, specialist referrals, and ongoing care coordination. When AI-generated summaries contain errors or omissions, the consequences extend beyond the initial consultation. Clinical verification and correction processes become essential, not optional.
Documented accountability for note accuracy matters. If a patient experiences harm due to incomplete or inaccurate AI-generated notes, responsibility must be clearly assigned. The current regulatory environment doesn't consistently address this question across all AI scribe implementations.
Deployment Requirements for Patient-Facing Technology
A productivity tool becomes a transformation project the moment it touches a patient. Responsible deployment in clinical settings requires specific structural elements:
Informed consent processes that ensure patients genuinely understand what they're agreeing to, including data handling, accuracy limitations, and clinical verification steps.
Clear alternatives for patients who refuse technology-mediated consultations, without penalty or reduced access to care.
Australian data considerations with transparent disclosure of where patient information travels and which jurisdictions govern its protection.
Clinical verification protocols that account for LLM limitations and assign clear responsibility for note accuracy.
Correction processes that allow patients to review and amend AI-generated summaries of their consultations.
Documented accountability structures that clarify who bears responsibility when technology fails or produces inaccurate records.
Patient communications written in plain language that explain the technology, its benefits, its limitations, and the patient's rights regarding its use.
The Pace of Adoption Versus the Pace of Governance
The 18-month boom in AI scribe usage demonstrates how quickly useful technology can achieve widespread adoption. Regulatory frameworks, professional standards, and patient protection mechanisms move more slowly. This gap isn't unique to healthcare, but the consequences in clinical settings carry particular weight.
Healthcare systems need efficiency improvements. Clinician burnout is real. Administrative burden reduces time available for direct patient care. These problems demand solutions. But technology deployed before adequate safeguards are established creates risks that may ultimately undermine both patient trust and the technology's long-term viability.
The tension between innovation and protection is becoming acute. Speed of adoption isn't the only metric that matters. The quality of implementation, the robustness of governance, and the genuine protection of patient rights determine whether efficiency gains strengthen or weaken the healthcare system.
Progress belongs to organisations that define proof before deployment, align technology implementation with patient protection, and build capability rather than dependency. AI scribes offer genuine potential for administrative efficiency. Realising that potential without compromising patient safety, autonomy, and trust requires treating deployment as a governance project from the start.
Written by Jeff Anderson, Founder of Arrow Strategic Communications.
Jeff leads strategy, software delivery, and workflow transformation initiatives across Australia.
